Ganciclovir Treatment of Symptomatic Congenital Cytomegalovirus Infection: Results of a Phase II Study
Citations Over TimeTop 10% of 1997 papers
Abstract
Congenital cytomegalovirus (CMV) infection occurs in approximately 1% of newborns in the United States. A phase II evaluation was done of ganciclovir for the treatment of symptomatic congenital CMV infection. Daily doses of 8 or 12 mg/kg were administered in divided doses at 12-h intervals for 6 weeks. Clinical and laboratory evaluations sought evidence of toxicity, quantitative virologic responses in urine, plasma drug concentrations, and clinical outcome. A total of 14 and 28 babies received 8 and 12 mg/kg/day, respectively. Five additional babies received ganciclovir on a compassionate plea basis. Significant laboratory abnormalities included thrombocytopenia (< or = 50,000/mm3) in 37 babies and absolute neutropenia (< or = 500 mm3) in 29 babies. Quantitative excretion of CMV in the urine decreased; however, after cessation of therapy, viruria returned to near pretreatment levels. Hearing improvement or stabilization occurred in 5 (16%) of 30 babies at 6 months or later, indicating efficacy.
Related Papers
- → Ganciclovir Treatment of Congenital Cytomegalovirus Infection: A report of two cases(1993)22 cited
- → Midwives' and women's understanding of cytomegalovirus infection during pregnancy(2023)1 cited
- → Cytomegalovirus infection of the skin(1982)32 cited
- → Cytomegalovirus and its Association with Multiple Infections: A Case Report(1984)1 cited
- → Progress in infant hearing-impaired with cytomegalovirus infection(2010)